Category: Cross-cutting Innovation and Collaboration – Work in Progress

Enhancing Clinical Trial Access and Enrollment for Acute Leukemia Patients: An Innovative Single-Institution Experience of the Leukemia Expanded Access Program

A McKinney, R. Tolley, J. Zeidner

UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

1. Background

Early engagement and streamlined pathways are critical for increasing clinical trial enrollment in acute leukemia, where timely therapy initiation is essential. The Leukemia Expanded Access Program (LEAP) was designed to expedite patient evaluation, enhance clinical trial accrual, and minimize hospitalizations at the University of North Carolina at Chapel Hill's Lineberger Comprehensive Cancer Center

2. Goals

LEAP was developed to:

- Expedite access for newly diagnosed acute leukemia patients while undergoing diagnostic testing
- Reduce the time from referral to patient provider visit
- Accelerate clinical trial screening and enrollment
- Decrease unnecessary hospitalizations and inpatient resource use
- Establish an efficient, scalable model for early patient engagement

3. Solutions and Methods

Traditionally, new patient referrals for acute leukemia would take intake 14–21 days before an attending provider visit, delaying diagnostic workup and trial eligibility determination. LEAP streamlines this process through:

- A dedicated electronic medical record (EMR) inbox for real-time tracking of leukemia referrals.
- Integrated research advanced practice provider (APP) model, improving coordination between clinical and research teams.
- Creation of pre-prepared lab kits for select trials to prevent delays.
- Structured scheduling with built-in time for trial consent discussions.

4. Outcomes

Since September 2023, LEAP has evaluated 126 patients (8 per month on average), with a median time to LEAP consultation of 3 days. Approximately 70% of LEAP referrals were from community providers. After LEAP visit, new patient provider visits are established within 6 days, significantly reducing the pre-LEAP timeframe of 18 days. Since September 2023, 52/126 (42%) patients were screened for clinical trials at the time of the LEAP visit and 38/52 (73%) enrolled in an interventional clinical trial. Overall clinical trial accrual significantly improved since the implementation of LEAP. Prio to LEAP (January-September 2023) monthly clinical trials accrual averaged 5 patients/month. Monthly clinical trial accrual rates increased to 9.3 patients/month from October-December 2023 and 10.2 patients/month in 2024.

This streamlined approach has contributed to a 70 percent increase in leukemia clinical trial accruals, from 2023 (n=73) to 2024 (n=124). LEAP played a pivotal role in this growth by expediting the evaluation process, improving trial matching efficiency, and enhancing patient access to investigational therapies.

Category: Cross-cutting Innovation and Collaboration – Work in Progress

5. Learned and Future Directions

Our findings suggest that a structured outpatient pathway can improve clinical trial enrollment and patient access to novel therapies.

Future directions include expanding this model to other hematologic malignancies and solid tumor programs to further optimize early-phase trial enrollment. This framework offers a scalable approach to enhancing clinical trial participation, reducing inpatient resource utilization, and improving patient-centered care.